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In its communication  to  the  European  Council  of Stuttgart in June  1983 
{"Biotechnology  :  The  Community's  role",(COM  (83)-328 final),  the  Commission 
emphasised  the  importance of modern  biotechnology for  the  future of industrial, 
agricultural  developments  and  health  in  the  Community;  and  defined  the  factors 
which  account,  in  spite  of  Europe's  outstanding  capacities  in  the  study  and 
application  of  the  life  sciences,  for  the  current  relative  weaknesses  in  the 
Member·States  in biotechnology.  These  weaknesses  were  ascribed to: 
fragmentation of research efforts in basic  biotechnology and  in 
certain specific areas of the agro-food  and  chemical  sectors  and 
of the  health industries. 
a  shortage of technicians  and  scientists with  advanced training in the 
multidisciplinary fields  of modern  biotechnology, 
the  absence  in the  Community  of a  context supportive  and  encouraging  for 
biotechnology  in  such aspects  as  : 
access at competitive prices  to  raw materials  of agricultural 
origin 
a  large internal market  with common  rules,  regulatory regimes 
and  laws  on  intellectual property 
logistic support  for  scientific and  industrial  infrastructure 
requiring European scale  :  data banks,  culture collections, 
centres of specialist expertise. 
Scientific  and  technical  objectives  in  biotechnology  were  outlined  in  the 
Framework  Programme  for  Community  S/T  Activities  1984-87  (COM(83)  260  final) 
adopted  by  the Council  in its Resolution of 25  July  1983  (O.J.  C 208/1). 
In  the  Stuttgart communication  cited,  the  Commission  defined  several  priority 
objectives  for  overcoming  present  weaknesses  and  declared  that  precise  and 
detailed proposals  for  Community  action  would  be  put  forward  in  the  course  of 
1983.  These  proposals  are  contained in  the present  communication,  embracing 
both the scientific and  technical  objectives and  the other necessary actions. 
- E  2  -2.  INSUFFICIENCIES  IN  THE  COMPETITIVENESS  OF  EUROPEAN  R&D  IN  MODERN  BIOTECHNOLOGY 
The  fundamental  importance  of  biotechnology in  economic  and  social  development  . 
is recognised  throughout  the  world. 
The  Member· States  of  the  Community,  strong  in  all  traditional  sectors  of 
applied  biology  and  in  the  research  base,  have  recently  committed  major 
investments  for  the  development  and  exploitation  of modern  biology.  In spite 
of these efforts,  the  Community  is being  outspent  by  the  U.S.  by  a  factor of 
2:1  in  public sector  research,  and  more  in  industry;  and  "outplanned"  by  the 
Japanese,  who  have  for  over  10  years  been  elaborating  a  coherently  planned 
approach  to  developments  in  the life  sciences  and  their industrial  and  medical 
applications,  in carefully selected sectors.  Not  unrelated  to  these  trends is 
the  evidence of a  substantial current European  deficit in  trade  and  in patents, 
and  of  continuing  emigration  of  European  scientists  to  the  United 
States,attracted particularly by  the  high quality infrastructure and  scientific 
environment. 
In  May  1983  a  U.S.  report,  prepared for  the  Office  of Science  and  Technology 
Policy  of  the  White  House  by  a  working  group  drawn  from  several  federal 
agencies,  assessed  the  competitive situation in biotechnology as  follows  : 
"Japan  will  be  the  stiffest  competitor  to  the  U.S.", 
countries of Western  Europe  : 
and  regarding  the 
"In  general,  the  lack  of  qualified  scientists  and  engineers  (particularly  in 
process  and  purification  technologies),  inadequate  industry/university 
cooperation,  and  belated  and  insufficient  R&D  funding  by  industry  and 
government,  are  probably  the  biggest barriers  to  commercial  competitiveness  in 
these  countries.  In  addition,  the  West  German  and  British  Governments  are 
concerned over  the  emigration of scientists  from  their countries,  many  of whom 
are  working  in  the  u.s ...  " 
A  report  (Oct.  1983)  from  the  Office  of  Technology  Assessment  of  the  U.S. 
Congress  similarly  sees  only  Japan  as  a  serious  competitor  to  the  U.S.  in 
biotechnlogy. 
- E  3  -3.  REASONS  FOR  THE  WEAKNESSES  OF  EUROPEAN  BIOTECHNOLOGY 
Ultimately,  the  European  weaknesses  can  be  ascribed  to  a  fragmentation  of 
effort into groups  and  programmes  too  small  for  the  dimensions  of the  problems, 
to  a  relative  scarcity  of qualified  staff and  to  the  absence,  at  Community 
level,  of  adequate  contextual  support  for  research, 
exploitation. 
development  and 
The  fragmentation,  isolation  and  even  dispersion  of  national  efforts  were 
acceptable  as  long  as  the  traditional  applications  of  biology  to  industry and 
agriculture could  develop  separately,  slowly  and  within  isolated  disciplines. 
This  situation  non  longer  holds  because  modern  biotechnology  is  in  essence 
multidisciplinary  in  its  approach,  complex  in  its  solutions,  and  is  being 
advanced  with great rapidity.  Any  attempt at improvement  within  the  Community 
has  to  take  into account  the  four  following  requirements  : 
critical mass 
- supportive  context  for  research 
supportive  context for  development 
interrelationships with sectoral policies 
+  Critical  mass  a  sufficient critical  mass  is  a  prerequisite  for  a 
strong  research  base,  able  through  pooling  of  skills  and  alliance  of 
disciplines  to  bring  a  wide  range  of possibilities  to  bear  on  any  among  many 
and diversified practical problems. 
+  Supportive  context for  research  :  research in  biotechnology cannot  be 
properly  implemented  in  the  absence  of extensive multidisciplinary training and 
without  appropriate  logistic  support  (data  banks,  collections  of  biotic 
materials,  major  centres  for  highly  specialised  expertise  and  technical 
facilities,  patent counselling ...  ). 
+  Supportive context for  development  :  progress  in biotechnology  and its 
exploitation depend  upon clear regulatory regimes at all stages  from  laboratory 
development  and  testing through marketing  to post-market monitoring. 
- E  4  -+  Interrelationships  with  sectoral  policies  :  the  economic  and  social 
impacts  of  biotechnology on  health,  agriculture  and  industry  are  such  that it 
is  no  longer  possible  to  envisage  an  evolution  of  sectoral  policies  or 
strategies  in  these  areas  which  could  be  independent  of  biotechnology  R&D. 
This  is particularly true within  the  Community  for  the agricultural  policy,  and 
for  the  public  health  domain  which  has  witnessed  a  rapid expansion  of medical 
costs  and  the  substantial  replacement  of  the  private  customer  by  the  state-
customer. 
4.  PROPOSED  COMMUNITY  ACTIONS 
Taking  into  account  those  of  its  existing  activities  that  are  related  to 
biotechnology,  among  which  the  central  R&D  action is  the  ongoing  programme  in 
biomolecular engineering,  the  Commission  proposes  the  following six priorities 
to  stimulate biotechnology  in the  Community  and  to  increase  competitiveness  in 
Europe's  hie-industries. 
A financial  statement is annexed.  The  tentative estimates relate  to  the  period 
1984-89, 
1984-87. 
and  within  this  period  are  consistent  with  the  Framework  Programme 
I.  RESEARCH  AND  TRAINING  : 
In conformity  with  the scientific and  technical  objectives of the  Framework 
Programme  1984-87  (COM(83)260  final),  the  following  lines  of  action  have 
been  identified, 
proposals. 
the  elements  of  which  will  be  presented  in  specific 
Each  action will  include research  and  training aspects  which are  intimately 
linked  in any  advanced  multidisciplinary activity. 
They  divide  into  "horizontal"  and  "specific" actions. 
"Horizontal  actions"  are  inherently  pre-competitive.  They  consist  of 
research  and  training  actions  in  basic  biotechnology  and  of  contextual 
measures  adapted  to  the  requirements of biotechnology  R&D.  The  projects for 
basic  biotechnology  are 
prevent  the  application 
focussed  upon  the  removal  of  bottlenecks  which 
of  modern  genetic  and  biochemical  methods  to 
industry  and  agriculture.  Key  areas  for  Community  research  to  be  carried 
- E  5  -out  in  cooperation  ·with  public  and  private  laboratories  have  been 
identified  ;  they  cover  the  sequences  of  events  and  processes  which  man 
must  understand  and  control  for  transforming  and/or  exploiting  on  a  large 
scale  the properties of those  species,  organisms,  tissues,  cultured cells, 
genes  and  gene  products  essential  for  new  industrial  and  agricultural 
developments. 
Another  "horizontal"  area of  growing  importance  is that  which  concerns  the 
information  infrastructure and  logistic support  for  the life sciences,  R&D 
through  databanks,  collections  of  biotic  materials  and  related 
information/communication  networks  and  the  sophisticated  data  capture 
technologies  which  are  generating  such  information  in  ever-increasing 
quanti ties.  Contextual  measures  and  projects  will  aim  to  maintain  and 
advance  these  essential  support  and  logistic  facilities  for  R  &  D  and  for 
its  exploitation  and  implementation  in  industry,  health  care  and 
agriculture. 
The  "specific  actions"  are  intended  to  stimulate  certain 
developments  within  well  defined  sectors  of  biotechnology 
particular 
which  can 
contribute  to  the  solution  of  problems  related  to  the  common  policy  in 
agriculture  and  in  the  health  cere  sector.  The  targets  chosen  have  been 
selected on  the  basis  of  their  intrainsic  importance,  and  in  view  of  the 
fact that,  under  the  normal  constraints  of commercial  criteria and  in  the 
still fragmented  state of the  European  market,  it is unlikely that they  can 
be  effectively pursued  by  industry.  With regard  to agro-food  and  chemical 
industries,  the  basic  priorities  obviously  lie  in  the  necessity  to  lower 
the  production  costs  of  raw  materials,  to  reduce  current  deficits  in 
industrial  feedstocks  and  to  maintain  the  competitiveness of  the  Community 
in  traditional  and  new  hie-industrial  processes.  Typical  examples  of  the 
work  to  be  carried out  through  joint research are  the assessment  and  design 
of new  raw materials  of agricultural  origin and  the  biochemistry  of poorly 
underst jOd  empirical  production  methods  for  agro-food  processing.  In  the 
health  industry  sector,  the  substitution  of  the  private  customer  by  the 
state customer  and  the  ever-increasing cost of health care provision,  have 
emphasised  the  economic  necessity  for  a  reorientation  of  R&D  towards  new 
medical  technologies.  The  major  objectives of Community  research should  be 
the  development  of  methods  for  prevention  or  rapid  treatment  of  certain 
common  (and socially costly)  diseases,  for  the  development of cheaper,  and 
- E  6  -more  precise  in  vitro  screening  systems  for  the  detection  of 
pharmacological  and  toxicological  activity,  and  for  the  definition  of new 
non-invasive  in  vivo  techniques  for  clinical diagnosis. 
These  research  activities  are  to  be  complemented  by  a  training  programme 
specifically  designed  for  reducing  the  present  shortage  of  appropriately 
trained  technicians  and  of  scientists  qualified in  basic  biotechnology,  a 
multidisciplinary activity not normally  taught  in universities.  Making  use 
of the  best  experts  from  throughout  the  Community  in  laboratories  of  high 
scientific level,  it is proposed  to  stimulate,  through  1-2 years  training 
contracts  or  short  duration  grants,  the  transfer  of  information  and 
competences  between  disciplines,  between  public  and  private  laboratories 
and  between  Member  States. 
* 
*  * 
The  following  four  priority  areas  are  designed  to  create  a  context 
supportive of the  adequate  development of biotechnology  in  the  Community. 
II.  CONCERTATION  OF  BIOTECHNOLOGY  POLICIES.  Biotechnology  is  a  broad  subject, 
because  of its  multi-disciplinary  bases,  and  the  multiplicity  of  sectors 
and  policy  areas  involved  in  its  development.  It is  therefore  essential 
for  coherence,  and  for  maximum  effectiveness  in  each  of  the  policy areas 
related  to  biotechnology,  to  have  a  central  activity  of  concertation 
inter-service,  international,  and  between  Community  and  Member  States. 
Such  conertation  demands  active  moni taring  and  assessment  of  strenghts, 
weaknesses,  and  emerging  opportunities and  challenges. 
The  principal  tool  to  be  used  in  the  moni taring  function  will  be  an 
expanded  series  of  networks,  established  in  cooperation  with  the  Member 
States  to  provide  an  ad-hoc  system  of collaboration  between  individuals, 
specialized  groups  and  institutions.  This  will  be  coupled  with  an 
information base,  regularly updated  by  scanning,  selecting,  interpreting 
and  storing in an  organized  way  the  incoming  flow  of information. 
In particular  these  activities  will  relate  to  the  4  domains  identified  as 
being of fundamental  importance  for  the  future  of European  biotechnology 
- E  7  -a)  Foundation capabilities  - strategic  strength in  biotechnolgy rests  on  a 
relatively  large  number  of  fundamental  disciplines  and  practical 
capabilities.  These  capabilities  must  be  present,  and  there  must  be 
active  monitoring  to  ensure  their  continued  strenght  in  a  rapidly 
changing situation. 
b)  Land  use  - as  noted  in  the  Commission's  recent communication  to  Council 
(COM ( 83) 500) ,  biotechnology  will  offer  a  growing  number  of  new 
opportunities  for  the  improvement  of  agricultural  production,  and  for 
increasing the  quantity and  range of  non-food  products  (timber,  animal 
feeds,  chemicals,  fuel ... ). 
c)  Relations  with  the  Developing  World  - Community  actions  in biotechnology 
can  make  significant contributions  to  the  needs  of the developing  world: 
both  through  the  programme  of Science  and  Technology  for  Development, 
and  through  contributing  specialist  advice  on  relevant  aspects  of  the 
Community  Development  Policy  (including,  for  example,  assessment of the 
risks of substitution for  major  Third  World  commodity  products,  and  the 
elaboration of policy responses). 
d)  Health  care  pharmaceutical  and  basic  health  research  are  of 
fundamental  importance  to  all  biotechnology  for  the  scale  and 
significance  of  their  research  efforts;  the  pharmaceutical  industry 
represents  the  technological  leading  edge,  particularly  in  the  all-
important  translation  of  scientific  breakthroughs  into  pure,  tested, 
economically produced,  marketable  products. 
Each  of  these  strategic  domains  is of  course  the  predominant concern  of a 
particular ministry  (in  Member  States)  or  service  (within  the  Commission); 
but  thE.  rich  and  proliferating  interactions  arising  from  biotechnology 
demand  a  horizontal  view,  if opportunities  are  to  be  seized  (cf.  the 
fertilisation  of  life  sciences  by  information  technology  bio-
informatics),  problems  avoided  (e.g.  uncompetitive  pricing of raw  materials 
for  the  fermentation  industry),  and  coherent policies adopted  (e.g.  between 
promotion  of  . innovation  and  protection  of  established  producers  or 
consumers) . 
- E  8  -Action  :  the  Commission  therefore  proposes  a  reinforcement of its resources 
for  effective  assessment  and  concertation  of  the  new  and  existing 
activities  which  bear  upon  the  5-year  biotechnology  action  plan.  Tasks 
will  be  defined,  in  consul tat  ion  with  Member  States,  as  necessary  to 
enhance  effectivenees  of  both  Community  and  national  actions  in 
biotechnology,  to  improve  contextual  conditions  (e.g.  disseminating 
knowledge  to  raise  the  quality  of  public  debate  on  acceptance),  and  to 
promote  its  development  in  all  useful  applications  and  the  supporting 
capabilities. 
III.  NEW  REGIMES  ON  AGRICULTURAL  OUTPUTS  FOR  INDUSTRIAL  USE 
Continuing research  and  development  in biotechnology is giving industry  the 
possibility to manipulate  raw  materials  and  to  produce  existing products  by 
new  methods  as  well  as  new  products.  Opportunities  are  thus  being created 
to adapt agricultural outputs  to  market  needs,  including  non-food  uses  and 
feedstocks  for  the  chemical  industry.  It is  therefore essential  that the 
regimes  for  raw  materials 
competitive  price  level  so 
investment policy. 
for  biotechnology  offer  a  free 
that  industry  can  establish  a 
choice  at 
long  term 
Action  in its Communication  on  the  Common  Agricultural  Policy  (COM(83)500 
final  2.10)  the  Commission  has  underlined  the  necessity  "to  provide 
Community  raw  materials  for  biotechnology  on  the  same  conditions  of 
competition as  for  external  competitors". 
The  Commission  intends  to  propose  to  the  Council  new  regimes  for  sugar  and 
starch for  industrial  use  which  will  attain this objectives. 
- E  9  -,, 
IV.  A  EUROPEAN  APPROACH  TO  REGULATIONS  AFFECTING  BIOTECHNOLOGY 
IV.l.  Biological Safety 
Public  and  parliamentary  opinion  is  divided  between  admiration  of  the  new 
discoveries  in  biotechnology,  and  concern  about  some  of  the  possible 
implications  or conjectural risks of their use.  This  concern is reflected 
in  the  extensive  discussions,  studies  and  reports  on  the  need  for 
regulation  and  control  of various  aspects  of the  life  sciences;  a  debate 
vigorously pursued  throughout  the  developed  industrial  world. 
Given  the  continued  level  of  widespread  public  and  political  concern, 
reflected  in  the  many  fora  mentioned,  and  in  the  similarly  persistent 
concern  with  issues  such  as  animal  welfare  and  their  use  in  tests,  which 
also  impinge  on  biotechnology,  it  is  clearly  a  normal  role  for  the 
Commission  to  ensure regulatory provision  to maintain rational  standards of 
public  safety;  to  this  end,  monitoring  the  social  dimensions  of 
biotechnology  and  their interfaces  with policy. 
Action  :  in  order  to  maintain  awareness  of  evolving  pressures  for  new 
policies  or  regulations,  a  monitoring  function  is  needed,  to  collate  at 
Community  level  the  evolving  views  of  national  regulatory  bodies  and 
interested international organisations  (OECD,  WHO,  Colli,cil  of Europe  etc.), 
and  hence  to  advise  the  Community  on  regulatory  initiatives  or 
international  negotiations.  This  function  can  be  appropriately  combined 
with  the  concertation role described in item II above,  and  provision for it 
is included  in the budget estimates. 
IV.2.  The  consumer  and  the bio-industry 
The  roles  of  the  public  authorities,  at  both  Community  and  Member  State 
level,  impinge  at  several  points  upon  the  "hie-industries" 
(pharmaceuticals,  agro-food etc.)  and  the  consumer.  The  Commission  seeks 
to  encourage  innovation,  harmonize  regulatory  regimes,  create  a  genuine 
- E  10  -common  market,  and  ensure  that regulations are  based  on rational  assessment 
and  well-informed  debate;  while  seeking always  to maintain  high standards 
of nutrition and safety. 
Action  as  with  the  previous  section  on  the  social  dimension  and 
biological  safety,  the  need  is to  maintain in  the  Commission  the capacity 
to monitor  the  situation,  and  hence  to cncert necessary policy discussions 
and  initiatives  accross  the  s~rvtces,  with  Member  States,  and  with  other 
relevant groups  (e.g.  consumer associations). 
IV.3.  The  Regulation of Products  and  their free Circulation 
The  bio-industries,  given  the  high  entry  costs  and  long  time  scales  (for 
both  R&D  work,  and  regulatory  approval),  have  great  need  of  the  full 
dimensions  of  the  European,  and  indeed  the  world,  markets  for  their 
products  or innovative processes. 
From  a  first review of the situation,  it would  appear  that the application 
of current  Community  regulations  in  the  various  fields  (pharmaceuticals, 
veterinary  medicines,  chemical  substances,  food  additives,  bioprotein 
feedstuffs)  will  meet  current  regulatory  needs,  provided  that  there  is 
close  cooperation  between  the  competent  authorities  in  the  Member  States 
and  the  Commission.  Such  cooperation  can  be  achieved  by  greater recourse 
to  the  existing institutional  or scientific  committees  and,  as necessary, 
use  of  the  new  information  procedure  for  technical  standards  and 
regulations  adopted  by  Council  in its directive 83/189/EEC  of 
28th  March  1983. 
Action  :  on  the  basis  of  its  experience  deriving  from  the  use  of  these 
various  instruments,  the  Commission  will  put  forward  general  or  specific 
proposals  appropriate  to  create 
development  of  the  activities 
a  regulatory  framework  sui  table  for  the 
of  the  bioindustries  and  for  the  free 
circulation  of  goods  produced  by  biotechnology.  In  its proposals,  the 
Commission will  be  careful  to introduce at Community  level measures  meeting 
urgent needs,  and  pursuing  the  common  interest in  line with  Article  36  of 
the  EEC  Treaty. 
- E  11  -V.  A EUROPEAN  APPROACH  TO  INTELLECTUAL  PROPERTY  RIGHTS  IN  BIOTECHNOLOGY. 
The  role of industrial property is to  secure  the  commercial  exploitation of 
proprietary R&D-results  in highly competitive  markets  and  simultaneously to 
permit the  beneficial  dissemination  and  exchange  of knowledge  in  the  field 
of activity  concerned.  Biotechnological  R&D  and  bio-industry  are rapidly 
evolving  and  expanding  at  the  international  level,  and  it is  therefore 
indispensable  that  the  industrial  property  laws  and  instruments  available 
in  the  Common  Market  match  the  need  of  science  and  industry  and  of  the 
Community's goals. 
Failure  to  provide  such  protection  for  intellectual  property  will  drive 
firms  to  protect  themselves  by  commercial  secrecy.  Such  secrecy  will 
inhibit  precisely  the  collaborative  patterns  of activity  which  are  needed 
in  this  complex  inter-disciplinary  field, 
obtained  from  the  individual  developments. 
Major  unresolved  issues  include 
if  maximum  benefit  is  to  be 
- the patentability of biotechnological  inventions  as  such  ; 
- the  implications  and  conditions associated  with  the  rules of practical 
protection requirements  and  procedures  (e.g.  associated with the  deposit 
of microorganisms  and  conditions  for release  to  third parties); 
- the additions  to  the  existing problems  concerning plant and  animal 
variety protection,  of complex  new  relations with patent law. 
Action 
- the  Member  States should be  invited to  share  with  the  Commission 
··information about  the  aims  and content of ongoing  and  planned  work, 
national  and  internationa(  regarding  the protection of biotechnological 
inventions or achievements  (e.g.  as  most  have  recently submitted  to 
the  OECD); 
- E  12  -- the  Member  States  and  the  Commission  should  seek  common  principles  and 
guidelines  for  the  management  and  dissemination of biotechnological  in-
formation  and  knowledge  arising  from  publicly  financed  R&D  in biotechno-
logy. 
The  industrial  property  issues in  biotechnology reinforce  the  need  for all 
Member  States  to  ratify  both  the  European  and  the  Community  Patent 
Conventions,  as  a  first  but  necessary  step  towards  a  basis  for  commonly 
accepted regulations. 
* 
*  *" 
It is  the  intention  of  the  Commission  to  complement  as  necessary  the  R&D 
activities  in biotechnology  by 
VI.  DEMONSTRATION  PROJECTS 
designed  to  facilitate  the  transition  between  research  developments  and 
full  scale  exploitation  on  a  commercial  basis.  These  will  be  framed  to 
relate also  to  the  other  Community  actions  bearing on  the  implementation of 
biotechnology.  Since  they  will  be  contingent  upon  the  outcome  of the  R&D 
actions,  their  precise scale,  status  and  timing will  be  estimated  in  due 
course. 
*" 
*"  * 
The  challenges  and  the  opportunities  presented  by  the  new  biotechnology  are 
clear.  An  effective  response  by  the  Community  and  the  Member  States  demands 
coherence  and  concertation,  themselves  depending  upon  an  act of political will. 
The  Commission  requests  the  agreement  of  the  Council  on  the  lines  of action 
proposed,  in order to set in motion  the  more  detailed definition of programmes 
and  procedures  which  will  inspire  and  reinforce  a  Community  policy  for 
biotechnology in Europe. 
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RESOURCE  REQUIREMENTS 
The  Biotechnology  Action  Plan  defines  the overall objectives and  coherence of a 
combination of measures  and  actions  which  are  diverse  in their nature,  resource 
requirements  and  timing.  Certain  elements  particularly  of  R&D  and 
assessment/concertation actions  - are  already fully  defined  and  casted;  others 
must  at  this  stage  be  seen  as  probable  requirements,  whose  detailed  costing 
must  await either further  investigation,  or  the  outcome  of the  R&D  itself. 
The  following  table  summarises  the  estimated requirements  for  the  5-year period 
July 1984-June  1989 
R&D  and  Training programme 
Assessment,  concertation and  non-R&D  contextual 
Preparatory actions  and  training,  on  commercial 
and  intellectual property 
Demonstration projects  in  the later years of the 
plan, 
Administrative  reinforcement related to regula-
tions,  market  regimes  and  development  policy 
Provisional  order-of-magnitude  total  for  the 
Biotechnology  5-year  Action Plan 
MioECU 
106 
6,6 
2,4 
80 
5 
200 
======= 
(i.e.average  40}:Mio  ECU  p.a.) 
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